+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07543289

Personalized Hydroxyurea Therapy in Nigerian Sickle Cell Disease Patients Using Pharmacogenetics and Modeling

Led by Ochuko Orherhe · Updated on 2026-10-27

100

Participants Needed

1

Research Sites

22 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying sickle cell disease in Nigerian patients to better understand how the drug hydroxyurea works for different individuals. This research focuses on the variability in patient responses due to differences in how the drug is processed and its effects, with the goal of creating a personalized treatment approach. The study involves 100 patients, including those already using hydroxyurea and those new to the therapy. Participants will be observed as part of a pharmacokinetic study where their blood and genetic markers will be collected and analyzed. Researchers will develop models to link drug exposure to clinical outcomes such as fetal hemoglobin levels and frequency of painful crises. Special models will also be created to optimize dosing for pregnant women, nursing mothers, infants, and children with sickle cell disease. During the study, participants will undergo various tests to measure drug levels, genetic factors, and clinical response markers. These include blood tests for fetal hemoglobin, blood cell volume, and monitoring of vaso-occlusive crises over six months. The study aims to provide knowledge that will improve hydroxyurea dosing guidelines for Nigerian sickle cell patients, enhancing clinical decisions and patient care.

CONDITIONS

Brief Title

Hydroxyurea Optimisation in Sickle Cell Disease

Research Team

O

Ochuko M. Orherhe, M.Phil.

B

Babatunde A Adeagbo, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here